Infectious bursal disease virus propolis live vaccine and preparation method thereof

By using water-soluble propolis as an adjuvant, the problems of immunosuppression and tissue damage in live vaccines against infectious bursal disease were solved, the immune protection effect of the vaccine was improved, and the safety and proliferative activity of the vaccine were enhanced, realizing the effective application of propolis adjuvant in live vaccines.

CN121445858APending Publication Date: 2026-02-03SHANDONG BINZHOU ANIMAL SCI & VETERINARY MEDICINE ACADEMY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202511334416.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-18
Publication Date
2026-02-03

AI Technical Summary

Technical Problem

Existing live vaccines for infectious bursal disease have problems with immunosuppression and tissue damage, and alcohol-extracted propolis adjuvants are not suitable for live vaccines, affecting viral proliferation activity.

Method used

Water-soluble propolis was used as an adjuvant, and was prepared by ultrasonic extraction and freeze-drying. The total flavonoid content was greater than or equal to 10 mg/mL. This propolis was used to prepare a live propolis vaccine for infectious bursal virus. Freeze-drying protectants and excipients were added to ensure the vaccine's immunoprotective effect and cell proliferation activity.

Benefits of technology

It significantly improved the level of immune response, reduced immunosuppression, enhanced the immune effect of natural adjuvants, avoided the impact of alcohol-extracted propolis on vaccine strains, and enhanced the safety and efficacy of vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121445858A_ABST
    Figure CN121445858A_ABST
Patent Text Reader

Abstract

The invention also discloses an infectious bursal disease virus propolis live vaccine and a preparation method thereof. The obtained infectious bursal disease virus propolis live vaccine can better induce and regulate host immune response, relieve toxic and side effects of the vaccine and reduce immunosuppression, and meanwhile has the effect of promoting growth. The vaccine product disclosed by the invention can be stably stored, and the virus multiplication capacity of the vaccine is not influenced. The obtained vaccine can replace a traditional live vaccine to be applied to the poultry breeding industry, and the poultry production efficiency can be remarkably improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biological products, specifically the field of cell and virus vaccines, and specifically relates to an infectious bursal virus propolis live vaccine and its preparation method. Background Technology

[0002] Currently, live vaccines for infectious bursal disease (IBD) are still the most commonly used in poultry farming. These primarily utilize isolated natural strains of the infectious bursal disease virus (IBDV) through continuous passage in chicken embryos and other hosts, allowing the pathogen's virulence to evolve from strong to weak during passage. Alternatively, the pathogen can be attenuated using physicochemical methods, resulting in embryo-to-virus vaccines produced via chicken embryos or cytotoxic vaccines produced via cells. However, in production and application, live virus vaccines still present certain problems. For example, while attenuated live vaccines can induce active immunity in chicken flocks within a short period, the immunization effect varies considerably due to factors such as maternal antibodies, and immunization failures occur frequently. While moderately virulent live vaccines can achieve good immunization effects, they can cause some damage to the bursa of Fabricius tissue, and their residual virulence may lead to immunosuppression. How to mitigate the tissue damage and immunosuppression caused by live vaccine immunization has become an urgent problem to be solved in improving the immunization effect of live IBD vaccines.

[0003] After a virus infects an animal, the host recognizes the unique molecular characteristics of the viral particle through pattern recognition receptors (PRRs), activating the inflammatory pathway and initiating inflammatory signaling pathways such as NF-κB. This leads to the production of pro-inflammatory cytokines, including interferon (IFN), colony-stimulating factor (CSF), chemokines, interleukin (IL), and tumor necrosis factor (TNF), which are key mediators of the antiviral innate immune and inflammatory responses. This process initiates the host's antiviral innate immune response, causing inflammation, eliminating the pathogen, and restoring homeostasis. However, viruses also possess autoimmune escape strategies, allowing them to evade host clearance and lead to persistent infection. The host can also regulate the body's immune and inflammatory responses through the NF-κB pathway; excessive immune regulation can also lead to over-inflammation and trigger immune-related pathological damage.

[0004] Natural propolis is rich in flavonoids, phenolic acids, and their derivatives. Studies have shown that the main bioactive substances in propolis, after being absorbed into the bloodstream by animals, can be transported to various organs of the body through the circulatory system, regulating numerous signaling pathways in key cellular processes, thereby exerting anti-tumor (Forma et al., 2021), anti-infection (Andrea M et al., 2020), anti-stress (Hotta S et al., 2020), and immune-enhancing effects (Sforcin JM et al., 2005). In terms of antiviral infection, propolis may primarily enhance host defense mechanisms in a non-specific manner, such as acting on the NF-κB signaling pathway, regulating the production of inflammatory cytokines by inhibiting NF-κB transcriptional activity, and thus exerting an immunomodulatory effect. A 2018 study by Takeda et al. showed that oral administration of 100-500 mg / kg / day of water-soluble propolis powder to mice enhanced the cytotoxic activity of NK cells (without affecting their proliferation), increased interferon-γ expression, and improved the body's antiviral capacity. Regarding poultry immune enhancement, Li Bing (2015) established an immunosuppressed chicken model by infecting SPF chickens with avian leukosis virus and reticuloendotheliosis virus. He found that subcutaneous injection of propolis extract (10 mg propolis / bird) could improve the immune function of immunosuppressed chickens, regulate the growth and development of the immune system, and increase immune organ indices, lymphocyte transformation, and cytokine secretion. Li Chenghong et al. (2016) used three types of propolis extracts—ethanol extract, water-ethanol extract, and water-ether-ester-ethanol extract—administered via drinking water (15 mg total flavonoids / group) to study the effect of propolis extract in drinking water on the immunity of SPF chicks to live infectious bursal disease vaccine. They found that propolis extract could significantly improve the immune organ indices of chickens after challenge with virulent strains, and increase the levels of IgG, IgA, IgM, IL-2, TNF-α, and IFNγ in serum, thereby improving the humoral and cellular immunity levels of chicks. However, the authors also found that there was no significant difference in the efficacy of propolis alcohol extract, water-based alcohol extract, and water-based ether-based ester-based alcohol extract when used in combination with vaccines and when used alone, the reasons for which require further investigation. In addition, propolis can enhance the antioxidant capacity of animals, thus combating oxidative stress damage caused by the large number of free radicals generated by various adverse factors in animal husbandry. Propolis can regulate blood lipids and fat deposition by affecting lipid absorption, transport, and oxidation, thereby improving the growth performance of poultry, enhancing overall health, and improving meat and egg quality.

[0005] The application of propolis as an immune adjuvant first appeared in 1989 when our unit invented the first fowl cholera propolis vaccine (CN89106871). Since then, various patents, research reports, and products related to propolis vaccines have emerged, but most are inactivated propolis vaccines for bacterial diseases. There are also a few research reports on propolis vaccines for viral diseases, but currently there are no marketed products, and research reports or related patents mainly focus on inactivated propolis vaccines or combined adjuvant vaccines. All of the above products and technologies use propolis ethanol extract as an adjuvant raw material, dissolving propolis in a high concentration of ethanol before preparing the vaccine according to a specific ratio. For live vaccines, the high ethanol content often affects the proliferative activity of the vaccine strain, seriously impacting the research on propolis live vaccines. Summary of the Invention

[0006] Purpose of the invention: In view of the safety risks such as immunosuppression caused by the need to further reduce the virulence of existing infectious bursal disease live vaccines, and the inability of existing alcohol-extracted propolis adjuvants to be used in infectious bursal disease live vaccines, the purpose of this invention is to provide a method for preparing infectious bursal disease propolis live vaccine using water-soluble propolis adjuvant, so as to improve the immune protection effect of the vaccine, regulate the level of immune response, and reduce immunosuppression.

[0007] Technical solution: In order to solve the above technical problems, the present invention provides an infectious bursal disease (IBDV) propolis live vaccine, wherein the IBDV propolis live vaccine comprises IBDV virus liquid and water-soluble propolis, wherein the total flavonoid content of the water-soluble propolis is greater than or equal to 10 mg / mL, and the solubility of the water-soluble propolis is greater than or equal to 830 mg / mL.

[0008] The water-soluble propolis is obtained by ultrasonic extraction and dewaxing using a 2-15% (w / v) lysine aqueous solution. The total flavonoid extraction rate of the water-soluble propolis is greater than or equal to 13%, and the relative dissolution rate of total phenols is greater than or equal to 120%.

[0009] The IBDV virus solution is a live strain of infectious bursal virus (IBDV) vaccine, prepared through chicken embryo passage or cell culture, and its live virus content should meet the relevant quality standards for veterinary biological products. For example, the live strain B87 used for IBDV vaccine should have a live virus content of greater than or equal to 10. 3.0 ELD 50 / Hane.

[0010] The amount of water-soluble propolis added to the live vaccine, based on the total flavonoid content, is 100 μg / mL to 1000 μg / mL. When the water-soluble propolis is used in vitro with the IBDV strain at a concentration of 100 to 1000 μg / mL for 8 hours, it does not significantly inhibit the proliferation of IBDV in cells.

[0011] The vaccine also includes a lyophilization protectant. Preferably, the lyophilization protectant includes a skim milk protectant or a heat-resistant lyophilization protectant without gelatin, added at a conventional dosage. Preferably, the vaccine also includes a stabilizer or excipient without gelatin, with a mass percentage of 5% to 15%.

[0012] The present invention also includes a method for preparing the infectious bursal virus propolis live vaccine, comprising the following steps:

[0013] 1) Preparation of water-soluble propolis: The propolis raw material is crushed and sieved to form a fine propolis powder, which is added to a lysine aqueous solution, stirred evenly, and ultrasonically extracted to obtain a propolis extract. The intermediate clear phase is collected by low-temperature centrifugation, and the water is removed by freeze drying to obtain water-soluble propolis.

[0014] 2) Preparation of water-soluble propolis adjuvant: Adjust the total flavonoid content of water-soluble propolis to 1-10 mg / mL;

[0015] 3) Preparation of live propolis vaccine for infectious bursal virus: IBDV vaccine strain is added to freeze-drying protectant and water-soluble propolis adjuvant prepared in step 1), and then freeze-dried to prepare vaccine.

[0016] In step 1), the concentration of the lysine aqueous solution is 2-15% (w / v), the solid-liquid ratio of propolis powder to lysine aqueous solution is 1:2-1:50 (g / mL), the ultrasonic temperature is 20-60℃, the ultrasonic power is 30-150W, the centrifugation temperature is 1-10℃, and the centrifugation speed is 10,000-15,000 rpm.

[0017] In step 2), the water-soluble propolis is diluted with physiological saline, and the total flavonoid content is determined using rutin as a standard substance, so that the total flavonoid content of the diluted water-soluble propolis is 1-10 mg / mL, and it is filtered with a 0.22 μm polyethersulfone filter membrane for sterilization.

[0018] In step 3), the amount of water-soluble propolis adjuvant added is 1% to 25% of the total volume of the vaccine before freeze-drying.

[0019] In step 3), the freeze-drying protectant includes skim milk or heat-resistant freeze-drying protectant, added according to conventional dosage, such as adding 50% skim milk (10% by mass or volume) or 50% heat-resistant freeze-drying protectant.

[0020] In step 3), the IBDV vaccine strain is a live strain used for infectious bursal virus vaccines, prepared through chicken embryo passage or cell culture, and its live virus content should meet the corresponding quality standards for veterinary biological products.

[0021] In step 3), the vaccine is prepared by using an IBDV vaccine strain that has been propagated by SPF chicken embryos or cultured in avian cell lines. After homogenization, the virus content, specificity, purity and other indicators are tested according to the vaccine manufacturing requirements. If they meet the requirements, the qualified vaccine strain is added to freeze-drying protectant, water-soluble propolis adjuvant, excipients, etc., and then freeze-dried to produce the vaccine.

[0022] Among them, the freeze-drying protectant and excipient can be gelatin-free protectants and excipients used in the market, such as skim milk or heat-resistant freeze-drying protectants, added according to the conventional dosage; the addition ratio of water-soluble propolis adjuvant is 1% to 25% by volume percentage.

[0023] Alternatively, the following method can be used: Component A is the vaccine virus, using an IBDV vaccine strain propagated in SPF chicken embryos or cultured in avian cell lines. After homogenization, the virus content, specificity, purity, and other indicators are tested according to existing vaccine manufacturing requirements, and all meet the requirements. The qualified vaccine virus is then freeze-dried with a suitable freeze-drying protectant. Component B is water-soluble propolis, using filtered and sterilized water-soluble propolis with the addition of an appropriate amount of stabilizer such as glucose. It is then dispensed into 2ml vials and freeze-dried. For clinical use, components A and B are reconstituted with vaccine diluent and diluted for injection in doses per bird.

[0024] The total flavonoid content of each bottle of water-soluble propolis ranges from 1 to 20 mg, the mass percentage of stabilizers such as glucose ranges from 5% to 15%, and the vaccine diluent is physiological saline (0.9% sodium chloride solution) or phosphate buffer.

[0025] Beneficial effects: The water-soluble propolis used in this invention as an adjuvant for the live vaccine against infectious bursal disease, administered together with the vaccine, effectively avoids the influence of ethanol in alcohol-extracted propolis on vaccine toxicity. Compared with single live vaccine administration, it significantly improves the level of immune response, enhances the immune effect of natural adjuvant, and reduces immunosuppression, which is the first of its kind in the world. Attached Figure Description

[0026] Figure 1 This figure shows the safety results of inoculating chicken embryo fibroblast cell lines with propolis adjuvant in Example 1.

[0027] Figure 2 This is a graph showing the safety results of inoculating chicken embryos with propolis adjuvant in Example 1.

[0028] Figure 3 This is a graph showing the viral proliferation titer results of chicken embryo fibroblast cell lines in Example 2, where propolis adjuvant was mixed with chicken infectious bursal virus.

[0029] Figure 4 This is a diagram showing the virus proliferation results of chicken embryos in Example 2, where propolis adjuvant was mixed with infectious bursal disease virus.

[0030] Figure 5 Figure showing the safety results of using comparative examples 1 and 3 to inoculate chicken embryo fibroblast cell lines.

[0031] Figure 6 The figure shows the viral replication titer results of chicken embryo fibroblast cell lines inoculated with a mixture of propolis and chicken infectious bursal virus using comparative examples 1 and 3. Detailed Implementation

[0032] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of the invention. Unless otherwise specified in the examples, conventional conditions or conditions recommended by the manufacturer are followed. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained through commercial purchases.

[0033] Example 1: Safety of water-soluble propolis

[0034] 1. Preparation of water-soluble propolis

[0035] The propolis raw material (purchased from Linqing Lvdu Bee Products Co., Ltd., item number: FJ20241225) was frozen and brittled at 0℃, then pulverized and sieved through an 80-mesh sieve to obtain uniform propolis fine powder. It was added to a 4% (w / v) lysine aqueous solution at a solid-liquid ratio of 1:8 (g / mL) of propolis to lysine, stirred evenly, and ultrasonically extracted at 240W power and 60℃ for 60 min to obtain propolis extract A. Propolis extract A was centrifuged at 10,000 rpm for 15 min at low temperature, and the intermediate clear phase was collected. Then, it was filtered under reduced pressure through qualitative filter paper to finally obtain clear and transparent propolis extract B.

[0036] Propolis extract B was freeze-dried to remove moisture. The specific freeze-drying steps were as follows: First, it was pre-frozen by rapid freezing at -40℃ for 2 hours; then it was transferred to a freeze dryer and dried under the following conditions: vacuum pressure 20 Pa, cold trap temperature -60℃, shelf temperature starting at -40℃ and slowly rising to -20℃, maintained for 12 hours; then a second drying was performed: vacuum pressure 8 Pa, shelf temperature in the range of 20℃ to 50℃, for 8 hours, to fully remove residual moisture, and finally obtain high-purity propolis water-soluble powder with lysine as a co-solvent.

[0037] The total flavonoid content was determined using rutin as a standard. The total flavonoid content of the prepared propolis was 18.3 mg / mL, and the total flavonoid extraction rate per unit propolis was 14.23%. The total phenol content in the sample was determined by UV-Vis spectrophotometry using gallic acid as a standard. The relative dissolution rate of total phenols was calculated to be 141.37%, based on the total phenol extraction rate obtained by the traditional ethanol reflux extraction method. Referring to the general rules of the Chinese Pharmacopoeia, the solubility of the extracted sample in water was determined to be 843.19 mg / mL.

[0038] Before use, dilute the water-soluble propolis total flavonoids with physiological saline to a concentration of 4 mg / mL, and then filter it through a 0.22 μm polyethersulfone membrane for sterilization.

[0039] 2. Effects of water-soluble propolis on the proliferation of chicken embryo fibroblast cell line DF-1

[0040] Based on the total flavonoid concentration, the water-soluble propolis solution prepared in step 1 was diluted with 0.01M PBS (pH 7.2–7.4) to form 10 concentration gradients: 2000 μg / mL, 1000 μg / mL, 600 μg / mL, 300 μg / mL, 150 μg / mL, 80 μg / mL, 40 μg / mL, 20 μg / mL, 10 μg / mL, and 5 μg / mL. 100 μl of each solution was added to a 96-well plate containing 90% confluent DF-1 cells (ATCC, CRL-12203), with four replicates per group. A control group without propolis and blank wells were also included, and the cells were incubated at 37°C. The integrity of the cell monolayers was observed every 12 hours. At 60 hours, the culture medium in each well was discarded, and the cells were washed once with growth medium. 10 μl of CCK-8 solution was added to each well, and the cells were cultured for another 4 hours. Cell proliferation activity was measured using a microplate reader. The absorbance at 450 nm was used as an indicator of cell growth; a higher absorbance value indicated more vigorous cell growth. Experimental results are shown below. Figure 1 The differences in OD values ​​showed that cell growth was negatively affected in the 2000 μg / mL propolis group (P = 0.004, P < 0.05), but the cell growth and viability in the 5 μg / mL to 1000 μg / mL groups were close to those of the control group. Therefore, water-soluble propolis at concentrations below 1000 μg / mL (P = 0.085, P > 0.05) did not inhibit the proliferation of the chicken cell line DF-1.

[0041] 3. Effects of water-soluble propolis on the proliferation activity of SPF chicken embryos

[0042] Based on the total flavonoid concentration, the water-soluble propolis solution obtained in step 1 was diluted with PBS to form six concentration gradients: 4000 μg / mL, 2000 μg / mL, 1000 μg / mL, 600 μg / mL, 300 μg / mL, and 150 μg / mL. These gradients were then inoculated into SPF chicken embryos incubated to 9 days of age, with 100 μL inoculated per embryo and 5 replicates per group. A control group without propolis was also included. Incubation continued. Embryo survival was observed by candling every 24 hours. At 14 days of age, embryos were frozen and killed. The embryos were removed, examined for lesions, cleaned of surface mucus, dried, and weighed. The results showed that at 14 days of age, all embryos in the 150 μg / mL to 4000 μg / mL groups were healthy and viable, with no visible damage. The embryos in some high-concentration groups showed greater weight gain than the control group. Figure 2 Therefore, water-soluble propolis at concentrations below 4000 μg / mL does not inhibit chicken embryo growth, while high concentrations promote chicken embryo growth.

[0043] Example 2: Effect of water-soluble propolis on the proliferation of infectious bursal virus

[0044] 1. Effects of water-soluble propolis on cells infected with infectious bursal virus.

[0045] The IBDV vaccine strain B87 (derived from the National Veterinary Microbial Culture Collection Center, strain number CVCCAV140) was diluted with PBS to a concentration of 1000 doses / mL. The water-soluble propolis solution prepared in Example 1 was diluted with PBS to form four concentration gradients: 1000 μg / mL, 500 μg / mL, 250 μg / mL, and 100 μg / mL. Each gradient was mixed with an equal volume of the diluted B87 strain and incubated at 4°C for 8 hours. Each sample group was then subjected to 10... -2 10 -3 ... 10 -7 Diluted 1-2 times and added to 96-well plates of DF-1 cells that had already formed an 80% cell monolayer for TCID testing. 50 Concentration determination was performed to evaluate the effect of water-soluble propolis solution on IBDV-infected cells. Results are as follows: Figure 3 As shown, compared with the virus control group without propolis, after 8 hours of in vitro co-treatment with IBDV strains, propolis solution of 100–1000 μg / mL had no significant inhibitory effect on the proliferation of IBDV in cells (P>0.05), indicating that water-soluble propolis in this concentration range does not affect the in vitro proliferation activity of IBDV.

[0046] 2. Effects of water-soluble propolis on chicken embryos infected with infectious bursal virus.

[0047] The IBDV vaccine strain B87 was diluted with PBS to a dose of 0.1 mL per bird. The water-soluble propolis solution prepared in Example 1 was diluted with PBS to three concentration gradients: 1000 μg / mL, 500 μg / mL, and 250 μg / mL. Each gradient was mixed with an equal volume of the diluted B87 strain and incubated at 4°C for 8 hours. Each sample group was then subjected to 10 [units of measurement - the last part is missing]. -2 10 -3 10 -4 Dilute 0.2 ml to the chorionic allantoic membrane of 10-day-old SPF chicken embryos and inoculate each embryo with the solution. Observe for 7 days and calculate the ELD. 50 The concentration was used to evaluate the effect of water-soluble propolis solution on IBDV infection in chicken embryos. Results are as follows: Figure 4 As shown, compared with the virus control group without propolis, after 8 hours of in vitro co-treatment with propolis solution of 250–1000 μg / mL and IBDV strain, there was no significant inhibitory effect on IBDV proliferation in chicken embryos (P>0.05). Water-soluble propolis in this concentration range did not affect the in vivo proliferation activity of IBDV. Moreover, at high concentrations of propolis solution (1000 μg / mL), the proliferation ability of IBDV was improved (P=0.0119, P<0.05). High concentrations of propolis solution may promote the proliferation of IBDV in chicken embryos through some unknown mechanism.

[0048] Example 3: Preparation of Infectious Bursal Disease Virus Propolis Live Vaccine (Strain B87)

[0049] Qualified IBDV B87 strain vaccine virulence was harvested, aseptically homogenized, and divided into two equal portions for the preparation of two vaccine groups. One portion was mixed with water-soluble propolis to a total flavonoid content of 2000 μg / mL, and then rapidly freeze-dried with an equal volume of a freeze-drying protectant containing 50 mg / mL sucrose and 100 mg / mL skim milk powder to produce Group II vaccine component A. Simultaneously, 2000 μg / mL water-soluble propolis (filtered and sterilized) was mixed with glucose to a concentration of 50 mg / mL, dispensed, and freeze-dried to produce Group II vaccine component B. Before use, components A and B were reconstituted, mixed, and diluted according to the same procedure as Group I vaccine for use. Both methods of vaccine preparation can form stable freeze-dried clumps that dissolve rapidly upon addition of diluent, and meet the requirements for sterility testing, mycoplasma-free testing, and exogenous virus testing.

[0050] The two groups of vaccines were diluted to 0.2 mL per bird dose, and then each was subjected to 10 [tests / sessions]. -2 10 -3 10 -4 Dilute 0.2 mL to chorioallantoic membrane and inoculate 0.2 mL per embryo into 10-day-old SPF chicken embryos for ELD. 50Concentration testing showed that the IBDV viral load in both vaccines was greater than 1000 ELD. 50 .

[0051] Example 4: Effects of Infectious Bursal Disease Virus Propolis Live Vaccine (Strain B87)

[0052] The two vaccine groups (Group I and Group II) prepared in Example 3 were diluted to 10 doses / 0.2 mL and inoculated into 10 susceptible chicks aged 7 days (weighing between 46.5 g and 65.1 g). Simultaneously, a control group was established that received the B87 live vaccine strain without propolis adjuvant (IBDV-B87 group) and a non-immunized group containing only the diluted solution. Each chick received 0.2 mL via eye drop and oral administration. The chicks were observed for 21 days. No systemic adverse reactions were observed. Necropsy revealed no obvious gross lesions in the bursa of Fabricius. However, the average weight and bursa of Fabricius weight of the experimental chickens were significantly lower in the B87 live vaccine group (P = 0.0049, P < 0.05) and the average bursa of Fabricius weight (P < 0.0001) compared to the control group. The average weight of the experimental chickens in both vaccine groups (P... Ι =0.0194, P Ⅱ =0.004, P<0.05) and average bursa of Fabricius weight (P Ι =0.0039, P Ⅱ =0.0361, P<0.05) were all higher than the control group, and there was no significant difference between the two vaccine groups (P=0.0361, P<0.05). 体重 =0.220, P 法氏囊重 =0.632, P>0.05). The bursal body ratio was calculated using the formula "bursal body weight = bursal weight / body weight × 100". The bursal body ratio in the B87 live vaccine group was significantly lower than that in the control group (P<0.0001), but the bursal body ratio in vaccine group II was similar to that in the control group (P=0.9881). This indicates that immunization with vaccine group II, which added soluble propolis, had no significant effect on the bursa of Fabricius, an important immune organ in SPF chickens. Vaccine group I had a higher bursal body weight than the control group (P=0.0224, significant difference), and the average bursal weight of the bursa of Fabricius was higher than that of other experimental groups and the control group, suggesting that immunization with vaccine group I may have promoted the growth of the bursa of Fabricius in SPF chickens to some extent (Table 1).

[0053] Table 1. Average bursal volume ratio in SPF chickens after inoculation with live propolis vaccine for infectious bursal disease virus.

[0054]

[0055] Two groups of vaccines were diluted to 0.2 doses / 0.2 mL, and 0.2 mL was administered to 10 21-day-old SPF chickens, one dose per bird via eye drop / oral instillation. A separate, isolated, non-immunized group of 10 chickens was also established. Twenty-eight days post-vaccination, each group was challenged with live IBDV strain BJQ902 (Shandong Lvdou Biotechnology Co., Ltd.), one dose per bird via eye drop / nasal instillation (10 doses per bird). 5.0EID 50 Five healthy control chickens were also included. Four days after the viral challenge, the bursa of Fabricius was examined for lesions. In the control group, 100% (5 / 5) of the chickens showed lesions such as swelling and yellowing of the bursa of Fabricius, while in the two immunized groups, 100% (10 / 10) of the chickens had bursa of Fabricius of normal size.

[0056] Comparative Example 1

[0057] Referring to patent CN 117859879A, water-soluble propolis is prepared using reagents such as polyethylene glycol, and the method is as follows:

[0058] Polyethylene glycol 400, caprylic acid glyceride, and lecithin were mixed evenly in a mass ratio of 3:3:1 and heated to dissolve and form an extractant.

[0059] Similar to Example 1, the propolis raw material was frozen and brittled at 0°C, pulverized and sieved through an 80-mesh sieve to obtain uniform propolis fine powder. The powder was added to the extraction solution at a solid-liquid ratio of 2:7 (g / mL) of propolis to extractant, stirred evenly, and ultrasonically extracted at 100W power and 60°C for 60 minutes. The extract was then filtered to obtain the propolis extract.

[0060] Comparative Example 2

[0061] The reference paper is as follows: "Determination of Total Flavonoid Content and Study on Antitumor and Anti-inflammatory Effects of Propolis Extracted by Different Methods" (Hu Fuliang et al., 2005, China Food Journal):

[0062] The propolis raw material was crushed and passed through an 80-mesh sieve. Ultrapure water was added at a solid-liquid ratio of 1:8 (g / mL) between the propolis powder and water. The mixture was then soaked in a constant temperature water bath at 30°C overnight for extraction. Water-soluble propolis was obtained by filtration.

[0063] Comparative Example 3

[0064] The referenced paper, "The Influence of Propolis Adjuvants Prepared by Different Processes on Chicken Egg Yolk Antibody Levels" (Zhang Baokang et al., 1999, Chinese Journal of Veterinary Medicine), is as follows:

[0065] The propolis raw material was pulverized through an 80-mesh sieve using the same method as in Example 1. 85% ethanol was added at a solid-liquid ratio of 1:8 (g / mL) of propolis powder to ethanol. The mixture was extracted by reflux in a 50°C water bath for 2 hours. The extract was concentrated under reduced pressure and the ethanol was evaporated to dryness. KOH solution with a final concentration of 0.1M and propylene glycol were added at a solid-liquid ratio of 3:100 (g / mL) of propolis to solvent. The final propylene glycol content was 15%. The mixture was stirred evenly and filtered to obtain water-soluble propolis.

[0066] Similar to Example 1, using rutin as a standard, the total flavonoid content of the water-soluble propolis prepared in Comparative Examples 1 to 3 was determined to be 36.64 mg / mL, 0.61 mg / mL and 3.49 mg / mL, respectively, with corresponding total flavonoid extraction rates of 13.51%, 0.52% and 11.27% in the propolis.

[0067] Similar to Example 1, gallic acid was used as a standard, and the total phenol content in the sample was determined by ultraviolet-visible spectrophotometry. The total phenol extraction rate of the traditional ethanol reflux extraction method was used as the benchmark value, and the relative dissolution rate of total phenol was calculated. The relative dissolution rates of total phenol in Comparative Examples 1 to 3 were 131.37%, 5.01%, and 87.60%, respectively.

[0068] According to the general rules of the Chinese Pharmacopoeia, the solubility of the extracted samples in water was determined to be 53.59 mg / mL, 7.38 mg / mL, and 620.54 mg / mL.

[0069] Compared with the examples, the total flavonoid extraction rate and total phenol dissolution rate of Comparative Example 1 were similar, but its solubility in water was significantly lower; Comparative Example 2 was slightly soluble in water, and its total flavonoid extraction rate and total phenol dissolution rate were significantly lower; Although the solubility of Comparative Example 3 was relatively close, its total flavonoid extraction rate and total phenol dissolution rate were lower than those of the examples.

[0070] Since the total flavonoid content extracted by the method described in Comparative Example 2 was too low to be compared with the examples, Comparative Examples 1 and 3 were used to further verify the application effect.

[0071] The water-soluble propolis solutions of each comparative example were diluted with physiological saline to a total flavonoid content of 2 mg / mL, and then filtered through a 0.22 μM polyethersulfone membrane for sterilization. The effect of water-soluble propolis on the proliferation of the chicken embryo fibroblast cell line DF-1 was evaluated according to the method described in Example 1. Based on the total flavonoid concentration, the water-soluble propolis solutions prepared in Comparative Examples 1 and 3 were diluted with 0.01 M PBS (pH 7.2–7.4) to form 10 concentration gradients: 2000 μg / mL, 1000 μg / mL, 600 μg / mL, 300 μg / mL, 150 μg / mL, 80 μg / mL, 40 μg / mL, 20 μg / mL, 10 μg / mL, and 5 μg / mL. These gradients were added to 96-well culture plates containing 90% confluent DF-1 cells (ATCC, CRL-12203), 100 μL per well, with four replicates per group. Simultaneously, a control group without propolis and blank wells were set up, and cultured at 37℃ for an extended period. The integrity of the cell monolayers was observed every 12 hours. After 60 hours, the culture medium in each well was discarded, and the cells were washed once with growth medium. Then, 10 μL of LCK-8 solution was added to each well, and the cells were cultured for another 4 hours. Cell proliferation activity was measured using a microplate reader. The absorbance at 450 nm was used as an indicator of cell growth; a higher absorbance value indicated more vigorous cell growth. Experimental results are shown below. Figure 5 In Comparative Example 1, the cell growth of groups treated with 600–2000 μg / mL propolis was significantly negatively affected (highly significant difference, P<0.01), but the cell growth and viability of groups treated with 5–300 μg / mL propolis were close to those of the control group. In Comparative Example 3, the cell growth of groups treated with 80–2000 μg / mL propolis was significantly negatively affected (highly significant difference, P<0.01). Therefore, water-soluble propolis prepared by both comparative methods had a greater impact on the proliferation of the chicken cell line DF-1 at higher concentrations.

[0072] Following the method described in Example 2, the effects of water-soluble propolis on cells infected with infectious bursal disease virus (IBDV) were compared. IBDV vaccine strain B87 was diluted with PBS to a concentration of 1000 doses / mL. Water-soluble propolis solution was also diluted with PBS to create four concentration gradients: 1000 μg / mL, 500 μg / mL, 250 μg / mL, and 100 μg / mL. Each gradient was mixed with an equal volume of the diluted B87 strain and incubated at 4°C for 8 hours. Each sample group was then subjected to 10 [units of measurement missing]. -2 10 -3 ... 10 -7 Diluted 1-2 times and added to 96-well plates of DF-1 cells that had already formed an 80% cell monolayer for TCID testing. 50 Concentration determination was performed to evaluate the effect of water-soluble propolis solution on IBDV-infected cells. Results are as follows: Figure 6As shown, compared with the virus control group without propolis, in Comparative Example 1, propolis solutions of 500–1000 μg / mL, after being co-treated with the IBDV strain in vitro for 8 hours, significantly inhibited the proliferation of IBDV in cells (highly significant difference, P<0.01). In Comparative Example 3, propolis solutions of 100–1000 μg / mL in all groups significantly inhibited the proliferation of IBDV in cells (highly significant difference, P<0.01). Therefore, the water-soluble propolis prepared by the two comparative methods is not suitable for preparing IBDV propolis live vaccine.

Claims

1. A live propolis vaccine for infectious bursal disease virus, characterized in that, The infectious bursal disease propolis live vaccine comprises IBDV virus liquid and water-soluble propolis, wherein the total flavonoid content of the water-soluble propolis is greater than or equal to 10 mg / mL, and the solubility of the water-soluble propolis is greater than or equal to 830 mg / mL.

2. The infectious bursal virus propolis live vaccine according to claim 1, characterized in that, The water-soluble propolis is obtained by ultrasonic extraction and dewaxing using a 2-15% (w / v) lysine aqueous solution. The total flavonoid extraction rate of the water-soluble propolis is greater than or equal to 13%, and the relative dissolution rate of total phenols is greater than or equal to 120%.

3. The infectious bursal virus propolis live vaccine according to claim 1, characterized in that, The IBDV virus fluid is a live strain of infectious bursal virus used in vaccines, prepared through chicken embryo passage or cell culture, and its live virus content should meet the corresponding quality standards for veterinary biological products.

4. The infectious bursal virus propolis live vaccine according to claim 1, characterized in that, The amount of water-soluble propolis added to the live vaccine, based on the total flavonoid content, is 100 μg / mL to 1000 μg / mL.

5. The infectious bursal virus propolis live vaccine according to claim 1, characterized in that, The vaccine also includes a lyophilization protectant. Preferably, the lyophilization protectant includes a skim milk protectant or a heat-resistant lyophilization protectant without gelatin, added at a conventional dosage. Preferably, the vaccine also includes a stabilizer or excipient without gelatin, with a mass percentage of 5% to 15%.

6. The method for preparing the infectious bursal virus propolis live vaccine according to any one of claims 1 to 5, characterized in that, Includes the following steps: 1) Preparation of water-soluble propolis: The propolis raw material is crushed and sieved to form a fine propolis powder, which is added to a lysine aqueous solution, stirred evenly, and ultrasonically extracted to obtain a propolis extract. The intermediate clear phase is collected by low-temperature centrifugation, and the water is removed by freeze drying to obtain water-soluble propolis. 2) Preparation of water-soluble propolis adjuvant: Adjust the total flavonoid content of water-soluble propolis to 1~10 mg / mL; 3) Preparation of live propolis vaccine for infectious bursal virus: IBDV vaccine strain is added to freeze-drying protectant and water-soluble propolis adjuvant prepared in step 1), and then freeze-dried to prepare vaccine.

7. The method for preparing the infectious bursal virus propolis live vaccine according to claim 6, characterized in that, In step 1), the concentration of the lysine aqueous solution is 2-15% (w / v), the solid-liquid ratio of propolis powder to lysine aqueous solution is 1:2-1:50 (g / mL), the ultrasonic temperature is 20-60℃, the ultrasonic power is 30-150W, the centrifugation temperature is 1-10℃, and the centrifugation speed is 10,000-15,000 rpm.

8. The method for preparing the infectious bursal virus propolis live vaccine according to claim 6, characterized in that, The amount of water-soluble propolis adjuvant added in step 3) is 1% to 25% of the total volume of the vaccine before freeze-drying.

9. The method for preparing the infectious bursal virus propolis live vaccine according to claim 6, characterized in that, The lyophilization protectant mentioned in step 3) includes skim milk or a heat-resistant lyophilization protectant, added according to the conventional dosage.

10. The method for preparing the infectious bursal virus propolis live vaccine according to claim 5, characterized in that, In step 3), the IBDV vaccine strain is a live strain used for infectious bursal virus vaccines, prepared by passage in chicken embryos or cell culture, and its live virus content should meet the corresponding quality standards for veterinary biological products.

Citation Information

Patent Citations

  • Method for preparation of propolis bacterin for curing avian cholera

    CN1030086C